Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine.

Autor:	Liang WS; Net/Bio Inc, Los Angeles, CA, United States.; Translational Genomics Research Institute (TGen), Phoenix, AZ, United States., Beaulieu-Jones B; Net/Bio Inc, Los Angeles, CA, United States.; University of Chicago, Chicago, IL, United States., Smalley S; Net/Bio Inc, Los Angeles, CA, United States., Snyder M; Net/Bio Inc, Los Angeles, CA, United States.; Stanford University, Stanford, CA, United States., Goetz LH; Net/Bio Inc, Los Angeles, CA, United States., Schork NJ; Net/Bio Inc, Los Angeles, CA, United States.; Translational Genomics Research Institute (TGen), Phoenix, AZ, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in pharmacology [Front Pharmacol] 2024 Mar 13; Vol. 15, pp. 1348112. Date of Electronic Publication: 2024 Mar 13 (Print Publication: 2024).
DOI:	10.3389/fphar.2024.1348112
Abstrakt:	In recent years, the development of sensor and wearable technologies have led to their increased adoption in clinical and health monitoring settings. One area that is in early, but promising, stages of development is the use of biosensors for therapeutic drug monitoring (TDM). Traditionally, TDM could only be performed in certified laboratories and was used in specific scenarios to optimize drug dosage based on measurement of plasma/blood drug concentrations. Although TDM has been typically pursued in settings involving medications that are challenging to manage, the basic approach is useful for characterizing drug activity. TDM is based on the idea that there is likely a clear relationship between plasma/blood drug concentration (or concentration in other matrices) and clinical efficacy. However, these relationships may vary across individuals and may be affected by genetic factors, comorbidities, lifestyle, and diet. TDM technologies will be valuable for enabling precision medicine strategies to determine the clinical efficacy of drugs in individuals, as well as optimizing personalized dosing, especially since therapeutic windows may vary inter-individually. In this mini-review, we discuss emerging TDM technologies and their applications, and factors that influence TDM including drug interactions, polypharmacy, and supplement use. We also discuss how using TDM within single subject (N-of-1) and aggregated N-of-1 clinical trial designs provides opportunities to better capture drug response and activity at the individual level. Individualized TDM solutions have the potential to help optimize treatment selection and dosing regimens so that the right drug and right dose may be matched to the right person and in the right context. Competing Interests: Author WL was a paid consultant of Net/Bio, Inc. Authors LG, NS, and SS are founders of Net/Bio, Inc. with equity. Authors MS and BB-J are unpaid consultants. (Copyright © 2024 Liang, Beaulieu-Jones, Smalley, Snyder, Goetz and Schork.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu